Key Highlights

  • Recursion Pharmaceuticals (RXRX) surpassed Q4 EPS forecasts with a loss of $0.21 per share versus analyst predictions of $0.30.
  • Quarterly revenue reached $35.54M, exceeding Wall Street estimates of $24.51M by approximately $11M.
  • A $30M milestone payment from Roche, received in October 2025, significantly boosted quarterly collaboration revenue.
  • Annual revenue for 2025 increased approximately 27% compared to 2024, reaching $74.7M following the Exscientia acquisition.
  • The company maintains $743.3M in cash reserves, sufficient to fund operations through 2028.

Recursion Pharmaceuticals (RXRX) experienced significant gains on Wednesday following the release of Q4 2025 financial results that exceeded analyst projections across key metrics.

The biotechnology firm, which leverages artificial intelligence for drug discovery, recorded a quarterly loss of $0.21 per share. This figure came in $0.09 better than the Street’s consensus estimate of $0.30.

Quarterly revenue totaled $35.54M, substantially above analyst expectations of $24.51M. This represents significant growth compared to the $4.5M generated during the corresponding quarter of the previous year.


RXRX Stock Card
Recursion Pharmaceuticals, Inc., RXRX

The primary catalyst behind the revenue outperformance was a $30M milestone payment from Roche, the Swiss pharmaceutical corporation, which the company received in October 2025. A substantial portion of this payment contributed to Q4 collaboration revenue.

While the revenue surge stems primarily from a singular milestone event, the strong results triggered positive investor sentiment in Wednesday’s trading session.

Annual Revenue Growth Reaches 27%

Recursion Pharmaceuticals generated total revenue of $74.7M for the complete 2025 fiscal year, representing approximately 27% growth compared to the prior year.

The revenue expansion benefited from incorporating results from Exscientia, the UK-based artificial intelligence drug discovery platform that Recursion merged with during 2024.

Research and development expenditures totaled $95.9M for Q4, declining roughly 2% on a year-over-year basis. General and administrative expenses demonstrated more dramatic improvement, decreasing approximately 56% YoY to $33.7M. These cost reductions contributed to a narrower net loss for the period.

The company’s balance sheet showed $743.3M in cash and cash equivalents at year-end 2025, up from $594.4M at the close of 2024.

Financial Runway Extends Through 2028

Recursion management indicated that existing cash reserves should sustain operations through 2028 without requiring additional capital raises. This guidance provides important clarity for investors monitoring the company’s cash consumption rate.

InvestingPro assigns Recursion a financial health rating indicating “weak performance,” underscoring that one strong quarter doesn’t resolve underlying operational challenges.

RXRX shares have faced considerable headwinds recently. The stock has declined 23.76% during the previous three-month period and fallen 57.67% over the trailing twelve months.

Wednesday’s rally occurred within this context of sustained weakness, with investors responding favorably to results that surpassed modest expectations.

Regarding earnings estimate revisions, Recursion received three upward adjustments and one downward adjustment during the 90-day period preceding this quarterly report.

RXRX shares closed Tuesday’s session at $3.53 before advancing on Wednesday’s earnings release.